NGM Bio Pinpoints Fourth Antibody Drug Candidate for Oncology Therapy Development BioPharm International, 25 Aug 2021 NGM Biopharmaceuticals has disclosed a fourth antibody drug candidate, NGM831, for development into an oncology therapeutic.